Related Experiment Video
Updated: Jan 20, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Isorhapontigenin, a resveratrol analogue selectively inhibits ADP-stimulated platelet activation
Divyashree Ravishankar1, Dina A I Albadawi1, Vishaant Chaggar1
1School of Pharmacy, University of Reading, Reading, UK.
Abstract:
Isorhapontigenin is a polyphenolic compound found in Chinese herbs and grapes. It is a methoxylated analogue of a stilbenoid, resveratrol, which is well-known for its various beneficial effects including anti-platelet activity. Isorhapontigenin possesses greater oral bioavailability than resveratrol and has also been identified to possess anti-cancer and anti-inflammatory properties. However, its effects on platelet function have not been reported previously. In this study, we report the effects of isorhapontigenin on the modulation of platelet function. Isorhapontigenin was found to selectively inhibit ADP-induced platelet aggregation with an IC50 of 1.85 microM although it displayed marginal inhibition on platelet aggregation induced by other platelet agonists at 100 microM. However, resveratrol exhibited weaker inhibition on ADP-induced platelet aggregation (IC50 > 100 microM) but inhibited collagen induced platelet aggregation at 50 microM and 100 microM. Isorhapontigenin also inhibited integrin αIIbβ3 mediated inside-out and outside-in signalling and dense granule secretion in ADP-induced platelet activation but interestingly, no effect was observed on α-granule secretion. Isorhapontigenin did not exert any cytotoxicity on platelets at the concentrations of up to 100 microM. Furthermore, it did not affect haemostasis in mice at the IC50 concentration (1.85 microM). In addition, the mechanistic studies demonstrated that isorhapontigenin increased cAMP levels and VASP phosphorylation at Ser157 and decreased Akt phosphorylation. This suggests that isorhapontigenin may interfere with cAMP and PI3K signalling pathways that are associated with the P2Y12 receptor. Molecular docking studies emphasised that isorhapontigenin has greater binding affinity to P2Y12 receptor than resveratrol. Our results demonstrate that isorhapontigenin has selective inhibitory effects on ADP-stimulated platelet activation possibly via P2Y12 receptor.
Related Concept Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
03:58Purification and Activation of Platelets from Murine Whole Blood
Inhibition of Cdk Activity
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
09:13Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
08:04Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

